Literature DB >> 22198467

Chances and risks of SGLT2 inhibitors.

Peter Mayer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22198467     DOI： 10.1007/s00210-011-0720-0

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN： 0028-1298            Impact factor:   3.000


× No keyword cloud information.
  25 in total

Review 1.  Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003.

Authors:  Richard W Nesto; David Bell; Robert O Bonow; Vivian Fonseca; Scott M Grundy; Edward S Horton; Martin Le Winter; Daniel Porte; Clay F Semenkovich; Sidney Smith; Lawrence H Young; Richard Kahn
Journal:  Circulation       Date:  2003-12-09       Impact factor: 29.690

Review 2.  Thiazolidinediones.

Authors:  Hannele Yki-Järvinen
Journal:  N Engl J Med       Date:  2004-09-09       Impact factor: 91.245

Review 3.  SGLT2 inhibition--a novel strategy for diabetes treatment.

Authors:  Edward C Chao; Robert R Henry
Journal:  Nat Rev Drug Discov       Date:  2010-05-28       Impact factor: 84.694

Review 4.  Renal glucose reabsorption inhibitors to treat diabetes.

Authors:  Clifford J Bailey
Journal:  Trends Pharmacol Sci       Date:  2011-01-04       Impact factor: 14.819

Review 5.  Sodium-glucose co-transporter 2 inhibitors: from apple tree to 'Sweet Pee'.

Authors:  Timothy C Hardman; Peter Rutherford; Simon W Dubrey; Anthony S Wierzbicki
Journal:  Curr Pharm Des       Date:  2010       Impact factor: 3.116

Review 6.  Sulfonylureas in NIDDM.

Authors:  L C Groop
Journal:  Diabetes Care       Date:  1992-06       Impact factor: 19.112

7.  Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial.

Authors:  Ele Ferrannini; Silvia Jimenez Ramos; Afshin Salsali; Weihua Tang; James F List
Journal:  Diabetes Care       Date:  2010-06-21       Impact factor: 19.112

Review 8.  The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes.

Authors:  S E Kahn
Journal:  Diabetologia       Date:  2003-01-11       Impact factor: 10.122

9.  Hypernatremia in the elderly.

Authors:  Olufemi Adeleye; Marquetta Faulkner; Tolulola Adeola; Gerard ShuTangyie
Journal:  J Natl Med Assoc       Date:  2002-08       Impact factor: 1.798

10.  Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial.

Authors:  Michael A Nauck; Stefano Del Prato; Juris J Meier; Santiago Durán-García; Katja Rohwedder; Martina Elze; Shamik J Parikh
Journal:  Diabetes Care       Date:  2011-08-04       Impact factor: 19.112
View more
  2 in total

Review 1.  Molecular Mechanisms Underlying the Cardiovascular Benefits of SGLT2i and GLP-1RA.

Authors:  Dorrin Zarrin Khat; Mansoor Husain
Journal:  Curr Diab Rep       Date:  2018-06-09       Impact factor: 4.810

Review 2.  A comprehensive review of the pharmacodynamics of the SGLT2 inhibitor empagliflozin in animals and humans.

Authors:  Martin C Michel; Eric Mayoux; Volker Vallon
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-06-26       Impact factor: 3.000
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.